Conducting Pre-Operative Evaluations
Structures pre-surgical risk assessment using ACC/AHA guidelines with cardiac and pulmonary clearance.
Why This Skill Exists
Pre-operative evaluation by a primary care clinician is the most common consultative role in ambulatory medicine. The 2014 ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Management provide the evidence-based framework, yet "medical clearance" is frequently misunderstood—the primary care role is to assess and optimize risk, not to "clear" patients for surgery. Perioperative cardiac events occur in 1-5% of non-cardiac surgeries, and 30-day mortality for major surgery ranges from 1-4% depending on procedure and patient factors.
Common errors include ordering unnecessary cardiac testing in low-risk patients (increasing cost and delaying surgery), failing to assess functional capacity, not adjusting perioperative medications appropriately, and providing vague clearance letters that do not communicate risk. This skill enforces the ACC/AHA stepwise algorithm to produce a structured risk assessment with specific recommendations for perioperative management.
Checkpoint A: Pre-Draft Intake (Mandatory)
- What is the planned surgical procedure and its surgical risk category (low, elevated)? Default: [REQUIRED]
- What is the urgency (elective, urgent, emergent)? Default: elective
- What is the patient's functional capacity in METs? Default: assess
- Does the patient have known or suspected cardiac disease (CAD, HF, valvular, arrhythmia)? Default: per history
- Does the patient have pulmonary disease (COPD, asthma, OSA)? Default: per history
- What medications is the patient currently taking (anticoagulants, antihypertensives, diabetes meds, inhalers)? Default: per med list
- What is the anticipated anesthesia type (general, regional, local/MAC)? Default: general
- What is the patient's BMI, recent labs (CBC, BMP, coags), and ECG status? Default: pending
Documents to Request
- Surgeon's procedure description with estimated blood loss and duration
- Anesthesia questionnaire if completed
- Recent cardiac testing (ECG, echocardiogram, stress test) if available
- Pulmonary function tests if known pulmonary disease
- Sleep study results if diagnosed OSA
- Current medication list with anticoagulant/antiplatelet details
- Recent labs: CBC, BMP, coagulation studies, A1c if diabetic, LFTs if hepatic concern
- Operative reports from prior surgeries noting anesthetic complications
- Advance directive documentation
Step 1: Surgical Risk Stratification
Classify the procedure per ACC/AHA categories:
| Risk Category |
Examples |
Estimated Cardiac Risk |
| Low risk (<1% MACE) |
Cataract, endoscopy, superficial procedures, breast biopsy, ambulatory surgery |
<1% |
| Elevated risk (≥1% MACE) |
Intraperitoneal, intrathoracic, vascular, orthopedic (hip/knee), head and neck, transplant |
1-5%+ |
For low-risk surgery: proceed without further cardiac testing regardless of patient factors (ACC/AHA Class III recommendation—testing not indicated).
Step 2: Cardiac Risk Assessment (ACC/AHA Stepwise Algorithm)
Step 2a: Is there an acute coronary syndrome or decompensated HF?
- If yes: defer elective surgery; cardiology consultation; manage acute condition first
Step 2b: Estimate surgical risk (Step 1 above)
- Low risk → proceed to surgery without cardiac testing
Step 2c: Assess functional capacity
- ≥4 METs (can climb a flight of stairs, walk 2 blocks on level ground, do heavy housework) → proceed without testing
- <4 METs or unable to assess → proceed to Step 2d
Step 2d: Calculate RCRI (Revised Cardiac Risk Index / Lee Index)
| RCRI Factor |
Points |
| High-risk surgery (intraperitoneal, intrathoracic, suprainguinal vascular) |
1 |
| History of ischemic heart disease |
1 |
| History of heart failure |
1 |
| History of cerebrovascular disease (stroke/TIA) |
1 |
| Diabetes mellitus on insulin |
1 |
| Creatinine >2.0 mg/dL |
1 |
| RCRI Score |
Risk of Major Cardiac Event |
Action |
| 0 |
3.9% |
Proceed; testing unlikely to change management |
| 1 |
6.0% |
Proceed; consider testing only if it will change management |
| 2 |
10.1% |
Pharmacologic stress test if results will alter management |
| ≥3 |
15%+ |
Stress testing recommended; cardiology consultation |
Do NOT order stress testing if the result will not change surgical decision.
Step 3: Pulmonary Risk Assessment
Assess risk using ARISCAT score or clinical judgment:
| Risk Factor |
Assessment |
| Known COPD/asthma |
Ensure optimal inhaler therapy; FEV1 <60% predicted = higher risk |
| Current smoking |
Counsel cessation ≥4 weeks before surgery (ideally 8 weeks); NRT permitted perioperatively |
| Obstructive sleep apnea |
Document STOP-BANG score; patient must bring CPAP to hospital; inform anesthesia |
| Obesity (BMI ≥40) |
Increased atelectasis and DVT risk; may need post-op ICU bed |
| Upper abdominal or thoracic surgery |
Highest pulmonary complication risk; incentive spirometry should be ordered |
Do NOT order routine preoperative PFTs unless:
- Unexplained dyspnea not adequately characterized
- Known lung disease requiring optimization before thoracic or upper abdominal surgery
- Lung resection planned (need to estimate post-resection pulmonary function)
Step 4: Perioperative Medication Management
| Medication |
Recommendation |
Rationale |
| Beta-blockers (chronic) |
CONTINUE through surgery |
Abrupt withdrawal → rebound tachycardia, ischemia (POISE trial) |
| Statins |
CONTINUE |
Pleiotropic perioperative benefit |
| ACEi/ARB |
HOLD morning of surgery |
Intraoperative hypotension risk; restart when euvolemic |
| Diuretics |
HOLD morning of surgery |
Hypovolemia risk |
| Aspirin (primary prevention) |
HOLD 7 days before surgery |
No proven perioperative benefit for primary prevention |
| Aspirin (secondary prevention / stent) |
CONTINUE unless high bleeding risk |
Discuss with surgeon and cardiologist; bare-metal stent: ≥30 days DAPT; DES: ≥6 months DAPT |
| Warfarin |
HOLD 5 days before surgery; bridge only if high thrombotic risk (mechanical valve, recent VTE) |
INR target <1.5 for most procedures |
| DOACs |
HOLD 24-48 hours before surgery (varies by agent and renal function) |
Rivaroxaban/apixaban: 24h for low-risk, 48h for high-risk; dabigatran: 48-72h if CrCl <50 |
| Insulin |
Reduce basal by 25-50% night before surgery; hold prandial insulin morning of surgery |
Hypoglycemia prevention |
| Metformin |
HOLD morning of surgery; restart when eating and renal function stable |
Theoretical lactic acidosis risk with contrast/renal insult |
| Sulfonylureas |
HOLD morning of surgery |
Hypoglycemia risk when NPO |
| Oral contraceptives / HRT |
Consider holding 4 weeks before major surgery if high VTE risk |
Thrombotic risk |
Step 5: Pre-Operative Assessment Letter
Structure the communication to the surgeon:
- Medical conditions relevant to surgical risk — list with severity and current management
- Cardiac risk assessment — RCRI score, functional capacity, need for further testing
- Pulmonary risk — COPD/OSA status, CPAP requirements, PFT results if obtained
- Medication management — specific hold/continue instructions with dates
- Laboratory requirements — any pending labs needed before surgery date
- Optimization recommendations — items to address before surgery (e.g., smoking cessation, A1c optimization, anemia correction)
- Risk statement — "The patient is at [low/moderate/elevated] perioperative risk based on RCRI and procedure classification. Risk-benefit discussion has been completed."
Do NOT write "cleared for surgery"—this implies a guarantee that no complication will occur and is medically and legally indefensible.
Checkpoint B: Post-Draft Alignment (Mandatory)
- Is the surgical procedure classified by risk category (low vs. elevated)?
- Has functional capacity been assessed in METs?
- Is the RCRI calculated with appropriate cardiac testing recommendation?
- Are all medication hold/continue instructions specific with timing?
- Does the assessment letter communicate risk clearly without using the word "cleared"?
Quality Audit
Guidelines
- Never order routine pre-operative testing (ECG, CXR, labs) for low-risk surgery in healthy patients—Choosing Wisely recommendation against routine preoperative testing
- Beta-blockers should never be initiated de novo on the day of surgery; the POISE trial showed increased stroke and mortality with perioperative beta-blocker initiation
- "Medical clearance" is not a medical term; the role of the primary care clinician is risk assessment and optimization, not guaranteeing surgical safety
- Asymptomatic carotid bruit does not require preoperative carotid imaging unless the patient has neurologic symptoms
- Pre-operative ECG is reasonable for patients with known cardiac disease, significant risk factors, or elevated-risk surgery, but is NOT indicated for low-risk surgery
- Post-menopausal bleeding, new murmur, or unexplained syncope discovered during preoperative evaluation require diagnostic workup before elective surgery proceeds
- Patients with drug-eluting stents within 6 months require cardiology consultation before stopping dual antiplatelet therapy
- Communicate the assessment to the surgeon, anesthesiologist, and patient—not just the chart
1---2name: conducting-pre-operative-evaluations3description: Structures pre-surgical risk assessment using ACC/AHA guidelines with cardiac and pulmonary clearance. Use when performing preop evaluations, assessing surgical risk, or providing medical clearance.4---5
6# Conducting Pre-Operative Evaluations
7
8Structures pre-surgical risk assessment using ACC/AHA guidelines with cardiac and pulmonary clearance.
9
10## Why This Skill Exists
11
12Pre-operative evaluation by a primary care clinician is the most common consultative role in ambulatory medicine. The 2014 ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Management provide the evidence-based framework, yet "medical clearance" is frequently misunderstood—the primary care role is to assess and optimize risk, not to "clear" patients for surgery. Perioperative cardiac events occur in 1-5% of non-cardiac surgeries, and 30-day mortality for major surgery ranges from 1-4% depending on procedure and patient factors.
13
14Common errors include ordering unnecessary cardiac testing in low-risk patients (increasing cost and delaying surgery), failing to assess functional capacity, not adjusting perioperative medications appropriately, and providing vague clearance letters that do not communicate risk. This skill enforces the ACC/AHA stepwise algorithm to produce a structured risk assessment with specific recommendations for perioperative management.
15
16---
17
18## Checkpoint A: Pre-Draft Intake (Mandatory)
19
201. What is the planned surgical procedure and its surgical risk category (low, elevated)? **Default: [REQUIRED]**
212. What is the urgency (elective, urgent, emergent)? **Default: elective**
223. What is the patient's functional capacity in METs? **Default: assess**
234. Does the patient have known or suspected cardiac disease (CAD, HF, valvular, arrhythmia)? **Default: per history**
245. Does the patient have pulmonary disease (COPD, asthma, OSA)? **Default: per history**
256. What medications is the patient currently taking (anticoagulants, antihypertensives, diabetes meds, inhalers)? **Default: per med list**
267. What is the anticipated anesthesia type (general, regional, local/MAC)? **Default: general**
278. What is the patient's BMI, recent labs (CBC, BMP, coags), and ECG status? **Default: pending**
28
29### Documents to Request
30
31- Surgeon's procedure description with estimated blood loss and duration
32- Anesthesia questionnaire if completed
33- Recent cardiac testing (ECG, echocardiogram, stress test) if available
34- Pulmonary function tests if known pulmonary disease
35- Sleep study results if diagnosed OSA
36- Current medication list with anticoagulant/antiplatelet details
37- Recent labs: CBC, BMP, coagulation studies, A1c if diabetic, LFTs if hepatic concern
38- Operative reports from prior surgeries noting anesthetic complications
39- Advance directive documentation
40
41---
42
43## Step 1: Surgical Risk Stratification
44
45Classify the procedure per ACC/AHA categories:
46
47| Risk Category | Examples | Estimated Cardiac Risk |
48|---|---|---|
49| Low risk (<1% MACE) | Cataract, endoscopy, superficial procedures, breast biopsy, ambulatory surgery | <1% |
50| Elevated risk (≥1% MACE) | Intraperitoneal, intrathoracic, vascular, orthopedic (hip/knee), head and neck, transplant | 1-5%+ |
51
52For low-risk surgery: proceed without further cardiac testing regardless of patient factors (ACC/AHA Class III recommendation—testing not indicated).
53
54---
55
56## Step 2: Cardiac Risk Assessment (ACC/AHA Stepwise Algorithm)
57
58**Step 2a: Is there an acute coronary syndrome or decompensated HF?**
59- If yes: defer elective surgery; cardiology consultation; manage acute condition first
60
61**Step 2b: Estimate surgical risk (Step 1 above)**
62- Low risk → proceed to surgery without cardiac testing
63
64**Step 2c: Assess functional capacity**
65- ≥4 METs (can climb a flight of stairs, walk 2 blocks on level ground, do heavy housework) → proceed without testing
66- <4 METs or unable to assess → proceed to Step 2d
67
68**Step 2d: Calculate RCRI (Revised Cardiac Risk Index / Lee Index)**
69
70| RCRI Factor | Points |
71|---|---|
72| High-risk surgery (intraperitoneal, intrathoracic, suprainguinal vascular) | 1 |
73| History of ischemic heart disease | 1 |
74| History of heart failure | 1 |
75| History of cerebrovascular disease (stroke/TIA) | 1 |
76| Diabetes mellitus on insulin | 1 |
77| Creatinine >2.0 mg/dL | 1 |
78
79| RCRI Score | Risk of Major Cardiac Event | Action |
80|---|---|---|
81| 0 | 3.9% | Proceed; testing unlikely to change management |
82| 1 | 6.0% | Proceed; consider testing only if it will change management |
83| 2 | 10.1% | Pharmacologic stress test if results will alter management |
84| ≥3 | 15%+ | Stress testing recommended; cardiology consultation |
85
86Do NOT order stress testing if the result will not change surgical decision.
87
88---
89
90## Step 3: Pulmonary Risk Assessment
91
92**Assess risk using ARISCAT score or clinical judgment:**
93
94| Risk Factor | Assessment |
95|---|---|
96| Known COPD/asthma | Ensure optimal inhaler therapy; FEV1 <60% predicted = higher risk |
97| Current smoking | Counsel cessation ≥4 weeks before surgery (ideally 8 weeks); NRT permitted perioperatively |
98| Obstructive sleep apnea | Document STOP-BANG score; patient must bring CPAP to hospital; inform anesthesia |
99| Obesity (BMI ≥40) | Increased atelectasis and DVT risk; may need post-op ICU bed |
100| Upper abdominal or thoracic surgery | Highest pulmonary complication risk; incentive spirometry should be ordered |
101
102**Do NOT order routine preoperative PFTs** unless:
103- Unexplained dyspnea not adequately characterized
104- Known lung disease requiring optimization before thoracic or upper abdominal surgery
105- Lung resection planned (need to estimate post-resection pulmonary function)
106
107---
108
109## Step 4: Perioperative Medication Management
110
111| Medication | Recommendation | Rationale |
112|---|---|---|
113| Beta-blockers (chronic) | CONTINUE through surgery | Abrupt withdrawal → rebound tachycardia, ischemia (POISE trial) |
114| Statins | CONTINUE | Pleiotropic perioperative benefit |
115| ACEi/ARB | HOLD morning of surgery | Intraoperative hypotension risk; restart when euvolemic |
116| Diuretics | HOLD morning of surgery | Hypovolemia risk |
117| Aspirin (primary prevention) | HOLD 7 days before surgery | No proven perioperative benefit for primary prevention |
118| Aspirin (secondary prevention / stent) | CONTINUE unless high bleeding risk | Discuss with surgeon and cardiologist; bare-metal stent: ≥30 days DAPT; DES: ≥6 months DAPT |
119| Warfarin | HOLD 5 days before surgery; bridge only if high thrombotic risk (mechanical valve, recent VTE) | INR target <1.5 for most procedures |
120| DOACs | HOLD 24-48 hours before surgery (varies by agent and renal function) | Rivaroxaban/apixaban: 24h for low-risk, 48h for high-risk; dabigatran: 48-72h if CrCl <50 |
121| Insulin | Reduce basal by 25-50% night before surgery; hold prandial insulin morning of surgery | Hypoglycemia prevention |
122| Metformin | HOLD morning of surgery; restart when eating and renal function stable | Theoretical lactic acidosis risk with contrast/renal insult |
123| Sulfonylureas | HOLD morning of surgery | Hypoglycemia risk when NPO |
124| Oral contraceptives / HRT | Consider holding 4 weeks before major surgery if high VTE risk | Thrombotic risk |
125
126---
127
128## Step 5: Pre-Operative Assessment Letter
129
130Structure the communication to the surgeon:
131
1321. **Medical conditions relevant to surgical risk** — list with severity and current management
1332. **Cardiac risk assessment** — RCRI score, functional capacity, need for further testing
1343. **Pulmonary risk** — COPD/OSA status, CPAP requirements, PFT results if obtained
1354. **Medication management** — specific hold/continue instructions with dates
1365. **Laboratory requirements** — any pending labs needed before surgery date
1376. **Optimization recommendations** — items to address before surgery (e.g., smoking cessation, A1c optimization, anemia correction)
1387. **Risk statement** — "The patient is at [low/moderate/elevated] perioperative risk based on RCRI and procedure classification. Risk-benefit discussion has been completed."
139
140Do NOT write "cleared for surgery"—this implies a guarantee that no complication will occur and is medically and legally indefensible.
141
142---
143
144## Checkpoint B: Post-Draft Alignment (Mandatory)
145
1461. Is the surgical procedure classified by risk category (low vs. elevated)?
1472. Has functional capacity been assessed in METs?
1483. Is the RCRI calculated with appropriate cardiac testing recommendation?
1494. Are all medication hold/continue instructions specific with timing?
1505. Does the assessment letter communicate risk clearly without using the word "cleared"?
151
152---
153
154## Quality Audit
155
156- [ ] Surgical procedure identified with risk category (low vs. elevated)
157- [ ] Urgency documented (elective, urgent, emergent)
158- [ ] Functional capacity assessed in METs with method documented
159- [ ] RCRI calculated with all six factors addressed
160- [ ] Cardiac testing ordered only when results would change management
161- [ ] Pulmonary risk assessed with OSA, COPD, smoking status documented
162- [ ] Medication management table completed with specific hold/continue dates
163- [ ] Anticoagulation bridging decision documented with rationale
164- [ ] Diabetic medication adjustment plan specified for NPO period
165- [ ] Labs ordered as appropriate for procedure and comorbidities (not reflexive panels)
166- [ ] Assessment letter structured without the phrase "cleared for surgery"
167- [ ] Advance directive status documented or discussion offered
168- [ ] Patient informed of perioperative risks relevant to their medical conditions
169- [ ] Follow-up plan established for post-surgical medication resumption
170
171---
172
173## Guidelines
174
175- Never order routine pre-operative testing (ECG, CXR, labs) for low-risk surgery in healthy patients—Choosing Wisely recommendation against routine preoperative testing
176- Beta-blockers should never be initiated de novo on the day of surgery; the POISE trial showed increased stroke and mortality with perioperative beta-blocker initiation
177- "Medical clearance" is not a medical term; the role of the primary care clinician is risk assessment and optimization, not guaranteeing surgical safety
178- Asymptomatic carotid bruit does not require preoperative carotid imaging unless the patient has neurologic symptoms
179- Pre-operative ECG is reasonable for patients with known cardiac disease, significant risk factors, or elevated-risk surgery, but is NOT indicated for low-risk surgery
180- Post-menopausal bleeding, new murmur, or unexplained syncope discovered during preoperative evaluation require diagnostic workup before elective surgery proceeds
181- Patients with drug-eluting stents within 6 months require cardiology consultation before stopping dual antiplatelet therapy
182- Communicate the assessment to the surgeon, anesthesiologist, and patient—not just the chart